Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: Implications for adult vaccination

Germaine Hanquet*, Pavla Krizova, Palle Valentiner-Branth, Shamez Ladhani, J. Pekka Nuorti, Agnes Lepoutre, Jolita Mereckiene, Mirjam Knol, Brita A. Winje, Pilar Ciruela, Maria Ordobas, Marcela Guevara, Eisin Mcdonald, Eva Morfeldt, Jana Kozakova, Hans Christian Slotved, Norman Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary CorcoranArie Van Der Ende, Didrik F. Vestrheim, Carmen Munoz-Almagro, Pello Latasa, Jesus Castilla, Andrew Smith, Birgitta Henriques-Normark, Robert Whittaker, Lucia Pastore Celentano, Camelia Savulescu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)

Abstract

Background Pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. Methods For each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 â ' IRR)∗100. Results After five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI â '4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI â '8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. Conclusion Overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.

Original languageEnglish
Pages (from-to)473-482
Number of pages10
JournalThorax
Volume74
Issue number5
DOIs
Publication statusPublished - 1 May 2019

Bibliographical note

Funding Information:
This study was co-funded by participating countries, the ECDC (SpIDnet project) and the European Commission (Horizon 2020, I-MOVE+).

Funding Information:
Funding this study was co-funded by participating countries, the ecDc (SpiDnet project) and the european commission (Horizon 2020, i-MOVe+).

Publisher Copyright:
© Author(s) (or their employer(s)) 2019.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Keywords

  • bacterial infection
  • clinical epidemiology

Fingerprint

Dive into the research topics of 'Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: Implications for adult vaccination'. Together they form a unique fingerprint.

Cite this